KURZPROTOKOLL
Ewing2008

Öffentlicher Titel	Studie zu Langzeitergebnissen bei der Behandlung von Ewing Sarkomen
Wissenschaftl. Titel	Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment (Ewing 2008)
Kurztitel	Ewing2008
Studienart	multizentrisch, prospektiv, randomisiert, offen/unverblindet, Investigator Initiated Trial (IIT), mehrarmig
Studienphase	Phase III
Erkrankung	Kinder: Sarkome: sonstige Studien für Sarkome Muskeln/Bewegungsapparat: Knochenkrebs (Sarkome): Ewingsarkom
Einschlusskriterien	- Diagnosis: Histologically confirmed Ewing sarcoma of bone or soft tissue - Age and sex: Either sex, age >48 months (for GPOH patients) and <50 years at the date of diagnostic biopsy. Younger or elderly patients may be reported to the appropriate office (see section 1.4) but are not included in this study - Registration: <= 45 days after diagnostic biopsy/surgery - Start of chemotherapy: <= 45 days after diagnostic biopsy/surgery - Informed consent: Must be signed prior to study entry - Performance status: Lansky or Karnofsky score > 50 %, may be modified for handicapped patients - Haematological parameters: Haemoglobin > 8 g/dl (transfusion allowed), Platelets > 80.000/µl (transfusion allowed), WBC > 2000/µl. Cardiac values: LVEF > 40%, SF > 28%
Ausschlusskriterien	- More than one cycle of other chemotherapy prior to registration - Second malignancy - Pregnancy and lactation - Concurrent treatment within any other clinical trial, except trials with different endpoints that due to the nature of their endpoints must run parallel to EWING 2008 e.g. trials on antiemetics, antimycotics, antibiotics, strategies for psychosocial support, etc... - Any other medical, psychiatric, or social condition incompatible with protocol treatment
Alter	4 - 49 Jahre
Gütesiegel	Deutsche Krebshilfe e.V.
Sponsor	Universitätsklinikum Münster
Förderer	Deutsche Krebshilfe e.V.
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT00824083 EudraCT 2008-003658-13